SLDB
NASDAQ · Biotechnology
Solid Biosciences Inc
$7.26
+0.58 (+8.68%)
Open$6.82
Previous Close$6.68
Day High$7.27
Day Low$6.82
52W High$7.37
52W Low$2.41
Volume—
Avg Volume783.2K
Market Cap437.08M
P/E Ratio—
EPS$-2.49
SectorBiotechnology
Analyst Ratings
Strong Buy
19 analysts
Price Target
+50.1% upside
Current
$7.26
$7.26
Target
$10.90
$10.90
$9.47
$10.90 avg
$14.24
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 294.33M | 265.12M | 296.42M |
| Net Income | 32.12M | 33.11M | 29.81M |
| Profit Margin | 10.9% | 12.5% | 10.1% |
| EBITDA | 56.98M | 46.74M | 49.34M |
| Free Cash Flow | 40.15M | 38.44M | 35.75M |
| Rev Growth | +16.9% | -8.0% | -9.5% |
| Debt/Equity | 0.34 | 0.27 | 0.36 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $207.18 | +0.96% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $353.93 | +1.58% | 24.4 | 188.06B |
| GILD | Gilead Sciences Inc | $138.26 | +0.11% | 20.0 | 170.34B |
| VRTX | Vertex Pharmaceuticals Inc | $454.97 | +1.42% | 29.2 | 115.53B |
| REGN | Regeneron Pharmaceuticals | $749.47 | +1.05% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.70 | +6.70% | 139.7 | 43.84B |